ArticleToxins2022
Combined Exposure to Multiple Mycotoxins: An Example of Using a Tiered Approach in a Mixture Risk Assessment.
Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review
- Occurrence of ergot alkaloids and deoxynivalenol in Brazilian wheat and cattle feed determined by UHPLC-MS/MS.Mycotoxin research · 2026Article
- Presence, Quantification, and Health Risk Assessment of Mycotoxins in Polyfloral Bee-Collected Pollen from Serbia.Toxins · 2026Article
- Overview of Current Regulatory and Methodological Approaches for the Risk Assessment of Mycotoxins.Toxins · 2026Review
- Article
- Behavioral and lethal effects of yeast based bioformulations on Bactrocera dorsalis.Scientific reports · 2026Article
- Article
- The use of canonical dose-response models for benchmark dose analysis of continuous toxicological data.Critical reviews in toxicology · 2025Review
- Paired metagenomic and chemical evaluation of aflatoxin-contaminated dog kibble.Frontiers in veterinary science · 2024Article
- Basic concepts of mixture toxicity and relevance for risk evaluation and regulation.Archives of toxicology · 2023Article
- Modified Mycotoxins and Multitoxin Contamination of Food and Feed as Major Analytical Challenges.Toxins · 2023Review
- Determination of in vitro hepatotoxic potencies of a series of perfluoroalkyl substances (PFASs) based on gene expression changes in HepaRG liver cells.Archives of toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humans are exposed to mycotoxins on a regular basis. Exposure to a mixture of mycotoxins may, therefore, result in a combination of adverse effects, or trigger the same effects. This should be accounted for when assessing the combined risk of multiple mycotoxins. Here, we show the outcome of using different approaches in assessing the risks related to the combined exposure to mycotoxins. We performed a tiered approach using assessment groups with a common target organ (kidney, liver and haematologic system), or a common adverse effect (phenomenon) (reduced white blood cell count), to combine the exposure to mycotoxins. The combined exposure was calculated for the individuals in this assessment, using the Monte Carlo Risk Assessment (MCRA) tool. The risk related to this combined exposure was assessed using toxicological reference values, e.g., health based guidance values. We show that estimating the combined risk by adding the single compounds' risk distributions slightly overestimates the combined risk in the 95th percentile, as compared to combining the exposures at an individual level. We also show that relative potency factors can be used to refine the mixture risk assessment, as compared to ratios of toxicological reference values with different effect sizes and assessment factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.